Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities

Butenschoen, Vicki Marie; Kelm, Anna; Meyer, Bernhard; Krieg, Sandro M.

doi:10.1007/s11060-019-03210-2

Cited by 7 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fatigue has been described as occurring frequently in spinal ependymoma patients, affecting up to 52% 17 . The assessed utility score using the EQ-5D questionnaire was 0.676 in our cohort, which is somewhat even lower than previously reported values of patients suffering from intracranial malignant gliomas (0.70–0.80 18 ) 19 . Interestingly, we found a significant difference in health-related quality of life between female and male patients, congruent with results presented in studies on quality of life in glioma patients, probably related to the greater dysfunction experienced by women at the same level of pain 20 – 22 .…”

Section: Discussioncontrasting

confidence: 82%

Quality of life and return to work and sports after spinal ependymoma resection

Butenschoen

Gloßner

Hostettler

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Adult spinal ependymoma presents a rare low-grade tumor entity. Due to its incidence peak in the fourth decade of life, it mostly affects patients during a professionally and physically active time of life. We performed a retrospective monocentric study, including all patients operated upon for spinal ependymoma between 2009 and 2020. We prospectively collected data on professional reintegration, physical activities and quality-of-life parameters using EQ-5D and SF-36. Issues encountered were assessed using existing spinal-cord-specific questionnaires and free-text questions. In total, 65 of 114 patients agreed to participate. Most patients suffered from only mild pre- and postoperative impairment on the modified McCormick scale, but 67% confirmed difficulties performing physical activities in which they previously engaged due to pain, coordination problems and fear of injuries after a median follow-up of 5.4 years. We observed a shift from full- to part-time employment and patients unable to work, independently from tumor dignity, age and neurological function. Despite its benign nature and occurrence of formal only mild neurological deficits, patients described severe difficulties returning to their preoperative physical activity and profession. Clinical scores such as the McCormick grade and muscle strength may not reflect the entire self-perceived impairment appropriately.

show abstract

Section: Discussioncontrasting

confidence: 82%

Quality of life and return to work and sports after spinal ependymoma resection

Butenschoen

Gloßner

Hostettler

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fatigue has been described as occurring frequently in spinal ependymoma patients, affecting up to 52% [18]. The assessed utility score using the EQ-5D questionnaire was 0.676 in our cohort, which is somewhat lower than previously reported values of patients suffering from intracranial malignant gliomas (0.70-0.80 [19]) [20]. Interestingly, we found a signi cant difference in health-related quality of life between female and male patients, congruent with results presented in studies on quality of life in glioma patients, probably related to the greater dysfunction experienced by women at the same level of pain [21][22][23].…”

Section: Discussioncontrasting

confidence: 71%

Return to work, activities of daily living and sports after spinal ependymoma resection: a monocenter experience with long-term follow-up

Butenschoen

Gloßner

Hostettler

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction: Adult spinal ependymoma presents a rare benign tumor entity. Due to its incidence peak in the fourth decade of life, it mostly affects patients during a professionally and physically active time of life.Methods: We performed a retrospective monocentric study, including all patients operated upon for spinal ependymoma between January 2009 and September 2020. We prospectively collected data on professional reintegration, physical activities and quality-of-life parameters using EQ-5D and SF-36. Issues encountered in returning to work and physical activities were assessed using existing spinal-cord-specific questionnaires and free-text questions.Results: In total, 65 of 114 patients operated on for spinal ependymomas agreed to participate. Most patients suffered from only mild pre- and postoperative impairment on the modified McCormick scale, but 67% confirmed difficulties performing physical activities in which they previously engaged due to pain, coordination problems and fear of injuries. We observed a shift from full- to part-time employment and patients unable to work, independently from tumor dignity and neurological function.Conclusion: Despite its benign nature and formal only mild neurological deficits occurring in patients suffering from spinal ependymoma, the studied population described severe difficulties returning to their preoperative physical activity and profession. Clinical scores such as the McCormick grade and muscle strength may not reflect the entire self-perceived impairment appropriately.

show abstract

“…The cost of care and management of a patient with glioma is comprised of the sum of the costs of imaging, laboratory work, surgical resection, pathology analysis, sequencing when available, radiation therapy (RT), concurrent temozolomide (TMZ), adjuvant TMZ, additional systemic treatments including novel interventions, lost wages for sick patients, and additional surgical intervention and/or additional RT as well as the cost of supportive care. Cost-effectiveness studies in glioma have previously examined several aspects of glioma care [ 74 ], including notably surgical intervention [ 75 ], chemotherapy and radiation [ 76 ], and novel interventions including imaging [ 77 , 78 ]. Molecular pathology has emerged as perhaps the single most important feature of discussion in tumor boards given both its relationship to outcomes and the potential for its leverage in altering management.…”

Section: The Cost Of Care and Omics In Gliomamentioning

confidence: 99%

“…In this period, they identified a total cost of GBP 1978 to GBP 26,980, with neuropathology (GBP 434) and chemotherapy (GBP 440) representing a relatively smaller proportion of the cost and radiotherapy (GBP 8832) the largest [ 74 ]. In more recent studies, however, authors note the difficulties in carrying out cost analyses given the lack of QALY as the outcome measure and the prevalent use of overall survival or life years gained (LYG) [ 75 ], as well as the lack of quality of life values for specific health statuses or utilities [ 75 ]. A more recent study examining the cost of care in 13 countries in a global context confirms these limitations in determining the cost of care in glioma [ 81 ].…”

Section: The Cost Of Care and Omics In Gliomamentioning

confidence: 99%

Cost Matrix of Molecular Pathology in Glioma—Towards AI-Driven Rational Molecular Testing and Precision Care for the Future

et al. 2022

View full text Add to dashboard Cite

Gliomas are the most common and aggressive primary brain tumors. Gliomas carry a poor prognosis because of the tumor’s resistance to radiation and chemotherapy leading to nearly universal recurrence. Recent advances in large-scale genomic research have allowed for the development of more targeted therapies to treat glioma. While precision medicine can target specific molecular features in glioma, targeted therapies are often not feasible due to the lack of actionable markers and the high cost of molecular testing. This review summarizes the clinically relevant molecular features in glioma and the current cost of care for glioma patients, focusing on the molecular markers and meaningful clinical features that are linked to clinical outcomes and have a realistic possibility of being measured, which is a promising direction for precision medicine using artificial intelligence approaches.

show abstract

Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities

Cited by 7 publications

References 42 publications

Quality of life and return to work and sports after spinal ependymoma resection

Quality of life and return to work and sports after spinal ependymoma resection

Return to work, activities of daily living and sports after spinal ependymoma resection: a monocenter experience with long-term follow-up

Cost Matrix of Molecular Pathology in Glioma—Towards AI-Driven Rational Molecular Testing and Precision Care for the Future

Contact Info

Product

Resources

About